A PARP successor? Michigan academic team touts potential of an aging — but still experimental — AstraZeneca drug in DNA damage repair
AstraZeneca has already made billions on their PARP Lynparza, working alongside rivals like GSK, Pfizer and Clovis to demonstrate the widening potential of a drug that throws a monkey wrench in the DNA damage repair process — allowing drugs to kill off cancer cells. Now a group of investigators at the University of Michigan have published new research to show how a similar approach targeting Wee1 has the potential to do the same for tough-to-treat cases of advanced pancreatic cancer.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.